CancerLinQ LLC, a subsidiary of American Society of Clinical Oncology, and the American Society for Radiation Oncology (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ® and improve the care of cancer patients nationwide. ASTRO will provide guidance for the development of the CancerLinQ® platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery™ to improve the care of patients receiving radiation therapy.
Between half and two-thirds of all cancer patients receive radiation therapy, also known as radiotherapy, to cure cancer, control its spread and relieve symptoms such as pain. At present, however, important details about radiation dose and treatment schedule are often absent from the electronic health record systems used in many oncology practices. Through the partnership, experts will develop specialized indicators for radiation-related treatment outcomes and quality that can be incorporated into the CancerLinQ platform. Inclusion of these metrics will provide a much more complete and accurate characterization of the cancer care that patients are receiving, particularly for the many situations where radiation and chemotherapy are combined.
The partnership reflects CancerLinQ's goal to create a system that encompasses all of cancer care by bringing together expertise from throughout the cancer community, as well as ASTRO's mission to improve patient outcomes through research and education.
As an official partnering organisation of CancerLinQ, ASTRO will support professional member participation in the program, advocate for streamlined data integration between leading oncology electronic health systems, and strengthen CancerLinQ's role as a go-to resource for the healthcare community. ASTRO will have access to CancerLinQ Discovery™, which generates specially curated sets of de-identified clinical data from the CancerLinQ® platform for oncologists, researchers and analysts to create new clinical knowledge and improve patient outcomes. In addition, ASTRO will become a founding member of the CancerLinQ Oncology Leadership Council, a body of thought leaders and oncology-affiliated experts that advises the CancerLinQ Board of Governors.
CancerLinQ is a powerful database—created by oncologists for oncologists—made up of vast amounts of usable, searchable, real-world cancer information. This big data initiative will allow users to see trends among millions of patients by analyzing cancer patient medical records, uncovering patterns that can improve patient care, and enabling doctors to compare their care against that of their peers and recommended guidelines.
In addition to the radiation oncologists, CancerLinQ LLC—a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO®)—is forging important strategic alliances with national leaders and organisations that play important roles across the entire care continuum that support high-quality care for patients, including professionals representing the entirety of the care team, government agencies, academic research institutions, life sciences, technology experts and advocacy organizations.
Brought to you by Scope e-Knowledge Center, a world-leading provider of metadata services, abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
